Search

Displaying results 1751 - 1760 of 1777 in total
  1. Drug

    Amifampridine

    go.drugbank.com/drugs/DB11640
    Approved

    Firdapse (amifampridine) was formally approved by the US FDA for the treatment of adults with LEMS as recently as November of 2018 [L4819].

  2. Drug

    Molnupiravir

    go.drugbank.com/drugs/DB15661
    Investigational

    [L39050] Molnupiravir was also granted emergency use authorization by the FDA on December 23, 2021; however, it is not yet fully approved.[L39588]

  3. Drug

    Iberdomide

    go.drugbank.com/drugs/DB12101
    Investigational

    [L64055] The FDA granted iberdomide accelerated approval on August 13, 2026, in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received

  4. Drug

    Estradiol acetate

    go.drugbank.com/drugs/DB13952
    ApprovedVet approved

    Thus, estrone and the sulfate conjugated form, estrone sulfate, are the most abundant circulating estrogens in postmenopausal women [FDA Label].

  5. Drug

    Dronabinol

    go.drugbank.com/drugs/DB00470
    ApprovedIllicitInvestigational

    weight loss in patients with AIDS and for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments [FDA

  6. Drug

    Raloxifene

    go.drugbank.com/drugs/DB00481
    ApprovedInvestigational

    [A4977] Available in many countries worldwide, raloxifene was initially approved by the FDA in December, 1997 under the market name Evista® for the management and prevention of osteoporosis in postmenopausal

  7. Drug

    Elbasvir

    go.drugbank.com/drugs/DB11574
    Approved

    Approved in January 2016 by the FDA, Zepatier is indicated for the treatment of HCV genotypes 1 and 4 with or without [ribavirin] depending on the presence of resistance-associated amino acid substitutions

  8. Drug

    Inbakicept

    go.drugbank.com/drugs/DB16479
    Investigational

    [L50592] This combination product was approved by the FDA on April 22, 2024, for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without

  9. Drug

    Abdavomeran

    go.drugbank.com/drugs/DB15695
    Investigational

    [L15017, L15022] BNT162b1 received fast track designation by the FDA on July 13, 2020.[L15027]

  10. Drug

    Insulin human

    go.drugbank.com/drugs/DB00030
    ApprovedInvestigational

    Exubera was followed by Afrezza, a monomeric inhaled insulin developed by Mannkind Corporation, which received FDA approval in 2016. … While still available in the US, Afrezza has had similar concerns associated with its use, and had an FDA "black box" warning added to it to warn about use in patients with chronic lung disease.